- Current report filing (8-K)
February 28 2011 - 5:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): February 28, 2011
Impax Laboratories,
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware
|
|
001-34263
|
|
65-0403311
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
30831 Huntwood Avenue,
Hayward, CA
|
|
94544
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(510) 476-2000
|
Not
Applicable
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 4.01 Changes in
Registrant’s Certifying Accountant.
|
|
|
|
|
(a)
|
|
Dismissal of Previous Independent Registered
Public Accounting Firm
|
On February 28,
2011, the Audit Committee of Impax Laboratories, Inc. (the
“Company”) notified Grant Thornton LLP (“GT”) that it
had determined to dismiss GT as the Company’s independent registered
public accounting firm, effective as of February 28, 2011.
The reports of GT on
the Company’s consolidated financial statements as of and for the years
ended December 31, 2010 and 2009, did not contain an adverse opinion or
disclaimer of opinion, nor were they qualified or modified as to uncertainty,
audit scope, or accounting principles.
During the
Company’s fiscal years ended December 31, 2009 and December 31,
2010, and through February 28, 2011, there were no disagreements between
the Company and GT on any matter of accounting principle or practice, financial
statement disclosure, or auditing scope or procedure that, if not resolved to
GT’s satisfaction, would have caused it to make reference to the matter
in conjunction with its reports on the Company’s consolidated financial
statements for the relevant year and there were no reportable events as defined
in Item 304(a)(1)(v) of Regulation S-K.
The Company furnished
a copy of the above disclosures to GT and requested that GT provide a letter
addressed to the Securities and Exchange Commission stating whether or not it
agrees with the statements made above. A copy of GT’s letter will be
filed as an amendment to this current report on Form 8-K within two days of
receipt by the Company.
|
|
|
|
|
(b)
|
|
Engagement of New Independent Registered Public
Accounting Firm
|
Also on
February 28, 2011, the Audit Committee of the Company notified KPMG LLP
(“KPMG”) that it would engage KPMG as the Company’s
independent registered public accounting firm commencing February 28, 2011.
During the
Company’s fiscal years ended December 31, 2010 and 2009, and through
February 28, 2011, neither the Company nor anyone acting on its behalf
consulted with KPMG with respect to either (i) the application of
accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company’s
consolidated financial statements, and no written report or oral advice was
provided by KPMG to the Company that KPMG concluded was an important factor
considered by the Company in reaching a decision as to the accounting,
auditing, or financial reporting issue or (ii) any matter that was the
subject of either a disagreement as defined in Item 304(a)(1)(iv) of
Regulation S-K or a reportable event as described in
Item 304(a)(1)(v) of Regulation S-K.
1
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: February 28, 2011
IMPAX LABORATORIES, INC
.
By:
/s/ Arthur A.
Koch,
Jr.
Name:
Arthur A. Koch, Jr.
Title: Senior Vice President, Finance, and
Chief
Financial Officer
3
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024